Mylan Launches Generic HIV Treatment


Lamivudine is designed to treat HIV-1 infection in combination with other antiretroviral agents.

Mylan has launched lamivudine tablets USP, 150 mg and 300 mg, which are the equivalent of ViiV Healthcare’s Epivir tablets.

Lamivudine is a nucleoside analogue reverse transcriptase inhibitor designed to treat HIV-1 infection in combination with other antiretroviral agents.

Patients should be aware that the HIV treatment has been linked with lactic acidosis and fatty liver disease. In addition, patients who are coinfected with HIV and hepatitis B virus may have severe acute exacerbations of hepatitis B when they discontinue lamivudine.

The treatment had US sales of around $27 million for the fiscal year ending on December 31, 2015, according to IMS Health.

Mylan announced the FDA’s approval of its abbreviated new drug application (ANDA) on April 6, 2016.

To date, Mylan has 265 ANDAs pending with the FDA that are worth around $110 billion in annual brand sales.

Related Videos
male pharmacist using digital tablet during inventory in pharmacy | Image Credit: sofiko14 -
Pharmacist holding medicine box in pharmacy drugstore. | Image Credit: I Viewfinder -
Pharmacy Drugstore Checkout Cashier Counter | Image Credit: Gorodenkoff -
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk -
Capsules medicine and white medicine bottles on table | Image Credit: Satawat -
Human cell or Embryonic stem cell microscope background | Image Credit: Anusorn -
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg -
Biosimilar pharmaceutical drug bottle on blue background. | Image Credit: Carl -
Pharmaceutical manufacture background with glass bottles with clear liquid on automatic conveyor line. | Image Credit: wacomka -
Bottle and scattered pills on color background, top view | Image Credit: New Africa -
© 2024 MJH Life Sciences

All rights reserved.